Literature DB >> 17911361

The relationship between cerebrospinal fluid biomarkers and depression in elderly women.

Pia Gudmundsson1, Ingmar Skoog, Margda Waern, Kaj Blennow, Sigurdur Pálsson, Lars Rosengren, Deborah Gustafson.   

Abstract

OBJECTIVE: Cerebrospinal fluid (CSF) biomarkers including the 42 amino-acid form of beta-amyloid (Abeta42), total tau protein (T-tau), and the CSF/serum albumin ratio are markers of brain pathology and metabolism. Abeta42 and T-tau are sometimes used to discriminate geriatric depression from mild forms of Alzheimer disease (AD) in clinical studies. However, studies focusing on the relationship between these CSF biomarkers and geriatric depression are lacking.
METHODS: This was a cross-sectional study with a population-based sample of 84 nondemented elderly women in Sweden. Measurements included neuropsychiatric, physical, and lumbar puncture examinations, with Diagnostic and Statistical Manual of Mental Disorders, Third Revision-based depression diagnoses and measurement of CSF levels of Abeta42, T-tau, albumin, and serum albumin.
RESULTS: Fourteen women (mean age: 72.6 years) had any depression (11 with major depressive disorder [MDD]). Compared to women without depression, women with MDD had higher levels of Abeta42 and the CSF/serum albumin ratio. The CSF/serum albumin ratio was also higher in women with any depression. No differences in T-tau were observed; however, T-tau increased with age.
CONCLUSION: Higher levels of CSF Abeta42 were observed among elderly depressed women, in contrast to lower levels usually observed in AD, indicating potential neuropathological differences between the two disorders. Higher CSF/serum albumin ratios observed in depressed women point to potential vascular processes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911361     DOI: 10.1097/JGP.0b013e3180547091

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  36 in total

1.  Soluble amyloid-β levels and late-life depression.

Authors:  Ricardo S Osorio; Tyler Gumb; Nunzio Pomara
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 2.  Neurobiology of resilience in depression: immune and vascular insights from human and animal studies.

Authors:  Katarzyna A Dudek; Laurence Dion-Albert; Fernanda Neutzling Kaufmann; Ellen Tuck; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2019-09-13       Impact factor: 3.386

Review 3.  Current understanding of the neurobiology and longitudinal course of geriatric depression.

Authors:  Sara L Weisenbach; Anand Kumar
Journal:  Curr Psychiatry Rep       Date:  2014-09       Impact factor: 5.285

Review 4.  Pathogenesis of depression: Insights from human and rodent studies.

Authors:  C Ménard; G E Hodes; S J Russo
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

Review 5.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

6.  Depression following traumatic brain injury in mice is associated with down-regulation of hippocampal astrocyte glutamate transporters by thrombin.

Authors:  Chun-Shu Piao; Ashley L Holloway; Sue Hong-Routson; Mark S Wainwright
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

7.  "Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis.

Authors:  Mary Clare Masters; John C Morris; Catherine M Roe
Journal:  Neurology       Date:  2015-02-10       Impact factor: 9.910

8.  Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression.

Authors:  Breno S Diniz; Antonio L Teixeira; Rodrigo Machado-Vieira; Leda L Talib; Marcia Radanovic; Wagner F Gattaz; Orestes V Forlenza
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2014-08-22       Impact factor: 4.077

9.  CSF biomarkers of Alzheimer disease: "noncognitive" outcomes.

Authors:  Catherine M Roe; Anne M Fagan; Elizabeth A Grant; David M Holtzman; John C Morris
Journal:  Neurology       Date:  2013-11-08       Impact factor: 9.910

10.  Breaching the blood-brain barrier as a gate to psychiatric disorder.

Authors:  Hadar Shalev; Yonatan Serlin; Alon Friedman
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.